Medtronic conducted a post market clinical follow-up (pmcf) survey to seek out potential new risks and assess performance of the endeavor resolute rx coronary drug-eluting stent.Survey results from an interventional cardiologist in practice 7 years.In the past 12 months, the physician has used the endeavor resolute stent 60 times.8 of the smallest (2.25 x 8 mm), 52 intermediate (2.25 x 12 mm to 4.00 x 34 mm) sizes of these stents were used.The following device complaints were encountered in procedure when using the endeavor resolute product over the last 12 months: stent loss was reported in 1 cases and resulted in no clinical/patient impact.It was reported that the device did not perform as expected in terms of reaching the target lesion in 5 events due to the calcification being too strong.It was stated that reaching the target lesion was not achievable despite pre-dilatation.It was reported that the device did not perform as expected in terms of dilation of the target lesion in 1 event due to the calcification being too strong.It was stated that despite pre-dilatation, the vessel did not adequately expand.
|